One other tidbit this week: turns out we’d been given incorrect information about the Apomab drug trial ditching the placebo. This week (with some chagrin) oncology staff let us know Val’s Apomab trail is unchanged, and half the participants will still receive a placebo instead of the drug, although that Continue Reading